Related Experiment Video
Updated: Apr 22, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
Multi-level determinants of tuberculosis treatment completion in rural Uganda: A cross-sectional study
Munanura Turyasiima1,2, Daniel Muliika3, Gaston Turinawe4
1Department of Standards Accreditation and Patient Protection, Ministry of Health, Kampala, Uganda.
Background:
Tuberculosis (TB) treatment completion rates in high-burden countries like Uganda often fall short of the WHO End TB Strategy target of ≥90%. This study evaluated multilevel determinants of treatment completion to guide evidence-based improvement strategies in rural Western Uganda.
Methods:
We conducted a cross-sectional, multi-center analytical study of 224 patients with drug-susceptible TB across four public health facilities in Kakumiro District. Eligible participants had been on treatment for at least six months. Data collected via structured questionnaires were validated against facility TB registers. Multivariable logistic regression identified independent predictors, reported as adjusted odds ratios (AOR) with 95% confidence intervals (CI).
Results:
The treatment completion rate was 82.6% (185/224), with a 30.4% TB-HIV co-infection rate. Significant positive predictors included high TB knowledge (AOR = 14.0; 95% CI: 3.06-24.5), high economic status (AOR = 7.2; 95% CI: 1.63-31.5), belief in treatment efficacy (AOR = 6.2; 95% CI: 2.02-18.8), and respectful health worker behavior (AOR = 5.0; 95% CI: 2.15-11.83). Community-level support was critical, specifically religious/community leader advocacy (AOR = 4.2; 95% CI: 1.84-9.51) and community health worker (CHW) home visits (AOR = 3.5; 95% CI: 1.64-7.72). Waiting time less than 30 minutes (AOR = 6.3, 95% CI: 1.91-20.96) also positively impacted TB treatment completion. Major negative predictors were male gender (AOR = 0.3; 95% CI: 0.11-0.86), drug stockouts (AOR = 0.3; 95% CI: 0.11-0.70), belief in traditional cures (AOR = 0.3; 95% CI: 0.13-0.71), and stigma (AOR = 0.4; 95% CI: 0.16-0.80).
Conclusion:
Achieving the WHO End TB targets requires integrated, multilevel interventions. Efforts should focus on male-targeted engagement, strengthening supply chains to eliminate drug stockouts, enhancing CHW-led community outreach, and reducing stigma to ensure equitable treatment success.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Factors Affecting Illness
For instance, risk factors are connected to illness,...

